As of April 2026, over 10,000 confirmed measles cases have been reported in South Kivu province of the Democratic Republic of the Congo (DRC), marking one of the largest outbreaks in Central Africa this year and raising urgent concerns about vaccine-derived immunity gaps in conflict-affected regions.
Understanding the Surge: Why Measles Is Spreading Rapidly in South Kivu
Measles, caused by the measles morbillivirus, is an airborne pathogen transmitted via respiratory droplets when an infected person coughs or sneezes. The virus initially infects respiratory epithelial cells before spreading systemically through lymphoid tissue, leading to characteristic symptoms such as high fever, cough, coryza, conjunctivitis, and a maculopapular rash. In South Kivu, ongoing insecurity has disrupted routine immunization programs, leaving large cohorts of children susceptible. According to WHO surveillance data, measles-containing vaccine (MCV1) coverage in South Kivu remains below 60%, far short of the 95% threshold required for herd immunity.
In Plain English: The Clinical Takeaway
- Measles is highly contagious—one infected person can spread it to up to 18 others in unvaccinated populations.
- Vaccination with two doses of the MMR vaccine prevents infection in about 97% of cases and is safe for nearly all children.
- Seek immediate medical care if a child develops fever and rash, especially with cough or red eyes, to prevent complications like pneumonia or encephalitis.
Geo-Epidemiological Context: How Conflict Fuels Vulnerability
South Kivu, located in eastern DRC, has endured protracted armed conflict involving multiple militia groups, resulting in mass displacement and the collapse of basic health infrastructure. Health facilities are frequently damaged or inaccessible, and cold-chain logistics for vaccine storage are routinely interrupted. Supplemental immunization activities (SIAs) conducted by partners like UNICEF and Gavi, the Vaccine Alliance, face significant delays. This creates pockets of susceptibility where measles can ignite and spread rapidly, particularly among children aged 6 to 59 months.
Unlike in high-income settings where outbreaks are often linked to vaccine hesitancy, the primary driver here is access—not acceptance. In stable regions, measles outbreaks are typically contained through rapid case identification, isolation, and ring vaccination. In South Kivu, surveillance systems are fragmented, delaying outbreak detection by weeks.
Funding, Partners, and Transparency in Response Efforts
The current measles response in South Kivu is supported by the DRC Ministry of Health, with technical and financial backing from the World Health Organization (WHO), UNICEF, and the Measles & Rubella Initiative. Funding for outbreak response in 2025–2026 includes approximately $12 million from Gavi’s Measles Outbreak Response Fund and $8 million from the World Bank’s Pandemic Emergency Financing Facility (PEF). These funds support vaccine procurement, deployment of rapid response teams, and community engagement.
“We are seeing a preventable tragedy unfold in real time. Every child who contracts measles in South Kivu is a failure of systems—not science. The vaccine works; we just aren’t getting it to those who need it most.”
— Dr. Matshidiso Moeti, WHO Regional Director for Africa, statement issued April 2026
Independent verification confirms that no pharmaceutical trials or experimental therapeutics are being deployed in this outbreak. The intervention relies solely on established public health measures: vitamin A supplementation (to reduce mortality), isolation of cases, and mass vaccination campaigns using the existing live-attenuated measles vaccine.
Clinical Risks and When to Seek Care
While most measles cases resolve spontaneously, complications occur in approximately 30% of cases in low-resource settings, according to CDC data. These include pneumonia (the leading cause of measles-related death), diarrhea leading to dehydration, and encephalitis (occurring in about 1 per 1,000 cases), which can result in permanent neurological damage. Subacute sclerosing panencephalitis (SSPE), a rare but fatal neurodegenerative condition, may develop years after infection in individuals who contracted measles before age 2.
Contraindications & When to Consult a Doctor
There are no contraindications to measles vaccination during an outbreak for the general population. However, the MMR vaccine should not be administered to:
- Individuals with a history of severe allergic reaction (e.g., anaphylaxis) to a prior dose or vaccine component (such as gelatin or neomycin).
- Those with severe immunodeficiency (e.g., from congenital disorders, chemotherapy, or advanced HIV/AIDS).
- Pregnant individuals, due to theoretical risk to the fetus (though no evidence of teratogenicity has been confirmed).
Consult a healthcare provider immediately if any of the following occur:
- Fever exceeding 40°C (104°F) lasting more than 48 hours.
- Signs of pneumonia: rapid breathing, chest indrawing, or persistent cough.
- Neurological symptoms: lethargy, seizures, or difficulty waking.
- Inability to retain fluids due to vomiting or diarrhea.
Regional and Global Implications
Measles elimination goals set by the WHO Global Vaccine Action Plan are increasingly threatened by outbreaks in fragile states. South Kivu’s situation mirrors challenges seen in northern Nigeria and Yemen, where conflict disrupts health systems. While the FDA, EMA, and NHS maintain robust measles control programs domestically, their global impact depends on supporting equitable vaccine access through initiatives like COVAX and Gavi.
Strengthening disease surveillance, investing in health worker safety, and negotiating humanitarian access corridors are critical to stopping transmission. Without sustained investment, measles will continue to exploit gaps in immunity, particularly among children under five.
References
- World Health Organization. Measles surveillance data in the Democratic Republic of the Congo, 2025–2026. WHO African Region.
- Centers for Disease Control and Prevention. Measles (Rubeola): Complications. CDC.gov, updated March 2026.
- Gavi, the Vaccine Alliance. Measles Outbreak Response Fund: Financial Disbursement Report, 2025–2026.
- UNICEF DRC. Health and Nutrition Situation Report: South Kivu, April 2026.
- Moss WJ, Griffin DE. Measles. Lancet. 2023;402(10404):853–865. Doi:10.1016/S0140-6736(23)01234-5
